Dr Daniel Sargent reports that 40% of the costs of clinical trials go to monitoring data, much of which are irrelevant. By revamping monitoring practices, trial costs can be cut substantially.

Three young oncologists from different specialties and practice settings see the elusive work/life balance as less important as work/life choices when aiming for a gratifying life and career.

Dr John Marshall previews the upcoming 2015 Ruesch Symposium, in which policy makers, insurers, regulators, researchers, and patients debate about what therapies are worth pursuing in GI cancer.

Dr Sheetal Kircher says 30-something oncologists need to reset priorities, when after years of independent decisions, career choices must take into account spouse, family, and life outside of work.

Patient advocates have emerged as sophisticated stakeholders who understand the healthcare system and are knowledgeable about pertinent scientific developments in their disease area.

A new study provides more information about when men with prostate cancer may benefit from active surveillance, says Dr Gerald Chodak.

Experts take on the issue of value in cancer care -- among the hottest topics of ASCO 2015 -- and what is at stake if efforts to ensure value do not succeed in containing healthcare costs.

Genetic testing is now ordered in the treatment of numerous cancer types. Is it useful? Is it even reliable? Dr John Marshall and world-class experts tackle key questions for practicing clinicians.

Mounting evidence suggests diet and exercise help prevent cancer recurrence, but what changes should patients focus on? And what can and should doctors do to help cancer patients change their ways?

Protecting the rectum from radiation while treating prostate cancer may have some benefit, but the relative costs need to be considered, says Dr Gerald Chodak.